Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (7649)	8/27/2001 1:37:12 PM
From: Joe Krupa	Read Replies (3) \| Respond to of 14101

Wolf, "It'll all happen when it happens. At the moment things seem downright positive - but, she's come most of the way since becoming involved with Clarke Pharmaceuticals. Where ever the pendulum of the attitude of the street has happened to be, she has moved (slowly) towards bringing great products to huge markets still owning everything and not having any debt. No mean feat. Now its 'great comfort and great confidence' on ROBTV and an aggressive plan to own 100% of OXO." Well said. No doubt there is genius in her ways and history has been evidence to that. Anyone who thinks she will drop the ball now, out of incompetence or carelessness, should reconsider their opinion in the context of how this company has got to where it is today. joe

To: Montana Wildhack who wrote (7649)	9/4/2001 12:53:30 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Excerps from Provalis 2001 YE News (I guess by now its old news for some of you <g>) Good cash on hand at 8.7mm pounds. Health care division asset up by 1.1mm pounds. They claim .5mm pounds for launch of Pennsaid. Balance sheet improving considerably from last year. Health Care Division Revenues 1999 4.7mm pounds 2000 5.1mm 2001 6.2mm From .7mm to 1.1mm can be attributed to Pennsaid given a static to 10% revenue growth in other Health Care div products. And that's for only the initial 3 months, and no NICE. There is also the possibility that revenue, from other Health Care division products, could have shrunk, too. But that's stretching to the optimistic side. I guess no surprises here, especially given one of your (Wolf's) past projections. From www.provalis.com: The acquisition of Pennsaid, in the face of fierce competition for this commercially attractive product, was a key milestone for the division and reinforces its ability to grow this important medicine sales business. Pennsaid should be a significant product for the division following its launch at the end of March 2001 and subsequent selling by the expanded sales-force of 42 representatives. A high level of initial stocking and a number of repeat orders for this product have already taken place. In the Therapeutics R&D division, which is a much longer-term activity, a number of important stages were reached in the vaccine R&D programmes. Protein antigen candidates were selected or short listed for development and key patents were granted on these in the important USA and European markets. Development activities leading up to the start of clinical evaluation of these candidates is due to begin in the next financial year. Operational Performance Group sales from continuing activities in 2001 grew to £7.8m; an 18% increase over 2000. The Group's Healthcare division, which made up the bulk of these sales, saw its sale of medicines increase by 22% to £6.2m. Although this only includes a small contribution from the new product Pennsaid and a modest effect from the expanded sales force that has only been in place from April 2001, this growth was still over twice the industry average. The division remained in profit (£0.2m; 2000 £0.5m) despite the significant costs associated with the major increases in the sales force and infrastructure, and the launch costs of Pennsaid. In Medical Diagnostics, sales were £1.3m, 44% ahead of last year. As expected, the bulk of the sales were of Glycosal? and largely came from European and Far East markets. With the USA and Japanese approvals and NGSP accreditation coming in late 2000, mid way through the financial year, followed by sales preparation and training of our distributors' sales representatives, product launches in these and other markets using these approvals only began in earnest at the beginning of Spring 2001, and so made only a modest contribution to this year. Sales of Glycosal are expected to grow strongly in the year ahead. Following an increase in R&D spend of £0.5m the division recorded a loss for the year of £2.4m which was £0.3m greater than 2000. With the changing sales mix towards Glycosal? operational performance is expected to improve further as the new automated manufacturing facility comes on stream in 2002. Losses for the Group (after tax and exceptional items) decreased substantially from £7.5m to £4.4m, a £3.1m (41%) reduction. Corporate administrative costs were reduced by over £1.0m and reflect the Group's significantly refocused, streamlined and purposeful business approach. The loss per share reduced by 52% to 2.0p. Overall therefore, Provalis' operating divisions - the Healthcare division with the new product Pennsaid and its expanded sales force, and the Medical Diagnostics division with the growing sales of Glycosal? and Osteosal? - are laying the foundations to take them towards operational cash generation in line with our stated strategy. This will allow the Group to meet and subsequently expand Therapeutics and Medical Diagnostic R&D expenditure using internal cash resources. ... Net assets (liabilities) 2001 2000 ? Healthcare 1.5 0.4 ? Medical Diagnostics - 1.1 ? Therapeutics R&D 0.4 (0.3) Unallocated assets including cash and deposits 1.9 1.2 8.7 3.0 10.6 4.2 Provalis, Building NICEly!